← Leaderboards
Peter J Houghton
University Of Texas Hlth Science Center
$32,798,876
Attributed
$34,731,005
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$58,253,169 · 18
By mechanism
P01$31,591,511 · 9
N01$12,826,452 · 2
R01$8,485,534 · 4
U01$5,197,230 · 2
U19$152,442 · 1
Top collaborators
- Sandeep Burma4 shared
- Raushan Kurmasheva3 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Sandeep Burma$8,062,293
- Raushan Kurmasheva$2,024,146
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorXenograft ProcedureRhabdomyosarcomaPathway InteractionsChildhoodCell LineSignal PathwaySignal TransductionResponsePharmaceutical PreparationsSarcomaSirolimusBaseOsteosarcomaInhibitor/AntagonistApoptosisChildhood Solid NeoplasmDoseMalignant Childhood NeoplasmXenograft ModelChildNeoplastic CellResistanceMalignant Neoplasms
Grant awards (89)
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors$536,215
R01 · FY2024 · CA
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors$553,149
R01 · FY2023 · CA
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$487,604
U01 · FY2023 · CA
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$587,662
U01 · FY2022 · CA · contact PI
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors$544,810
R01 · FY2022 · CA · contact PI
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$600,685
U01 · FY2021 · CA · contact PI
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors$554,134
R01 · FY2021 · CA · contact PI
Pediatric Preclinical Testing Consortium: Research Programs non-CNS$315,184
U01 · FY2021 · CA · contact PI
Pediatric Preclinical Testing Consortium: Research Programs non-CNS$315,184
U01 · FY2020 · CA · contact PI
Pediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)$592,110
U01 · FY2019 · CA · contact PI
Pediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)$469,536
U01 · FY2018 · CA · contact PI
Studies of Childhood Sarcomas$1,624,423
P01 · FY2017 · CA · contact PI
Pediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)$610,422
U01 · FY2017 · CA · contact PI
Therapeutic Exploitation of Mutant BRAF for Astrocytoma$494,568
R01 · FY2017 · CA · contact PI
INSULIN-LIKE GROWTH FACTOR SIGNALING AS A THERAPEUTIC TARGET IN CHILDHOOD SARCOMAS$278,191
P01 · FY2017 · CA · contact PI
XENOGRAFT AND CELL LINE CORE$252,109
P01 · FY2017 · CA · contact PI
ADMINISTRATIVE AND BIOSTATISTICS CORE$198,502
P01 · FY2017 · CA · contact PI
Studies of Childhood Sarcomas$1,617,102
P01 · FY2016 · CA · contact PI
Pediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)$610,422
U01 · FY2016 · CA · contact PI
INSULIN-LIKE GROWTH FACTOR SIGNALING AS A THERAPEUTIC TARGET IN CHILDHOOD SARCOMAS$277,840
P01 · FY2016 · CA · contact PI
XENOGRAFT AND CELL LINE CORE$251,757
P01 · FY2016 · CA · contact PI
ADMINISTRATIVE AND BIOSTATISTICS CORE$198,151
P01 · FY2016 · CA · contact PI
Therapeutic Exploitation of Mutant BRAF for Astrocytoma$138,308
R01 · FY2016 · CA · contact PI
Studies of Childhood Sarcomas$1,619,923
P01 · FY2015 · CA · contact PI
Pediatric Preclinical Testing Consortium: Research Programs Non-CNS (U01)$608,421
U01 · FY2015 · CA · contact PI
Therapeutic Exploitation of Mutant BRAF for Astrocytoma$314,363
R01 · FY2015 · CA · contact PI
INSULIN-LIKE GROWTH FACTOR SIGNALING AS A THERAPEUTIC TARGET IN CHILDHOOD SARCOMAS$268,168
P01 · FY2015 · CA · contact PI
XENOGRAFT AND CELL LINE CORE$242,087
P01 · FY2015 · CA · contact PI
ADMINISTRATIVE AND BIOSTATISTICS CORE$188,479
P01 · FY2015 · CA · contact PI
Studies of Childhood Sarcomas$1,503,106
P01 · FY2014 · CA · contact PI
Therapeutic Exploitation of Mutant BRAF for Astrocytoma$298,347
R01 · FY2014 · CA · contact PI
INSULIN-LIKE GROWTH FACTOR SIGNALING AS A THERAPEUTIC TARGET IN CHILDHOOD SARCOMAS$261,047
P01 · FY2014 · CA · contact PI
XENOGRAFT AND CELL LINE CORE$234,949
P01 · FY2014 · CA · contact PI
ADMINISTRATIVE AND BIOSTATISTICS CORE$181,327
P01 · FY2014 · CA · contact PI
Studies of Childhood Sarcomas$1,505,297
P01 · FY2013 · CA · contact PI
Therapeutic Exploitation of Mutant BRAF for Astrocytoma$318,997
R01 · FY2013 · CA · contact PI
INSULIN-LIKE GROWTH FACTOR SIGNALING AS A THERAPEUTIC TARGET IN CHILDHOOD SARCOM$272,659
P01 · FY2013 · CA · contact PI
ADMINISTRATIVE AND BIOSTATISTICS CORE$192,524
P01 · FY2013 · CA · contact PI
XENOGRAFT AND CELL LINE CORE$184,104
P01 · FY2013 · CA · contact PI
PEDIATRIC PRECLINICAL TESTING PROGRAM$2,700,000
N01 · FY2012 · CA · contact PI
Rapamycin-Induced Selective Apoptosis in Malignant Cells$256,452
R01 · FY2012 · CA · contact PI
PEDIATRIC PRECLINICAL TESTING PROGRAM$2,791,925
N01 · FY2011 · CA · contact PI
XENOGRAFT STUDIES$317,882
P01 · FY2011 · CA · contact PI
MTOR AS A THERAPEUTIC TARGET IN PEDIATRIC SOLID TUMORS$267,036
P01 · FY2011 · CA · contact PI
Rapamycin-Induced Selective Apoptosis in Malignant Cells$256,452
R01 · FY2011 · CA · contact PI
PEDIATRIC PRECLINICAL TESTING PROGRAM$2,938,868
N01 · FY2010 · CA · contact PI
XENOGRAFT STUDIES$377,592
P01 · FY2010 · CA · contact PI
MTOR AS A THERAPEUTIC TARGET IN PEDIATRIC SOLID TUMORS$288,945
P01 · FY2010 · CA · contact PI
Rapamycin-Induced Selective Apoptosis in Malignant Cells$264,384
R01 · FY2010 · CA · contact PI
Pediatric Preclinical Testing Program$1,990,858
N01 · FY2009 · CA · contact PI
XENOGRAFT STUDIES$370,850
P01 · FY2009 · CA · contact PI
Rapamycin-Induced Selective Apoptosis in Malignant Cells$308,448
R01 · FY2009 · CA · contact PI
MTOR AS A THERAPEUTIC TARGET IN PEDIATRIC SOLID TUMORS$283,375
P01 · FY2009 · CA · contact PI
Studies of Childhood Solid Tumors$2,219,539
P01 · FY2008 · CA · contact PI
XENOGRAFT STUDIES$360,433
P01 · FY2008 · CA · contact PI
Rapamycin-Induced Selective Apoptosis in Malignant Cells$307,071
R01 · FY2008 · CA · contact PI
MTOR AS A THERAPEUTIC TARGET IN PEDIATRIC SOLID TUMORS$275,002
P01 · FY2008 · CA · contact PI
PEDIATRIC PRECLINICAL TESTING PROGRAM$2,404,801
N01 · FY2007 · CA · contact PI
Studies of Childhood Solid Tumors$2,156,053
P01 · FY2007 · CA · contact PI
XENOGRAFT STUDIES$324,740
P01 · FY2007 · CA · contact PI
Rapamycin-induced Selective Apoptosis in Malignant Cells$267,387
R01 · FY2007 · CA · contact PI
MTOR AS A THERAPEUTIC TARGET IN PEDIATRIC SOLID TUMORS$247,610
P01 · FY2007 · CA · contact PI
ADMINISTRATION$163,604
P01 · FY2007 · CA · contact PI
Studies of Childhood Solid Tumors$1,656,211
P01 · FY2006 · CA · contact PI
CORE--XENOGRAFT FACILITY$285,821
P01 · FY2006 · CA · contact PI
Rapamycin-induced Selective Apoptosis in Malignant Cells$275,373
R01 · FY2006 · CA · contact PI
Studies of Childhood Solid Tumors$1,648,971
P01 · FY2005 · CA
MTOR as a Therapeutic Target in Childhood Cancer$300,375
R01 · FY2005 · CA
Rapamycin-induced Selective Apoptosis in Malignant Cells$282,000
R01 · FY2005 · CA
TARGETING STRESS-ACTIVATED AKT-MTOR DRIVEN TRANSLATION$152,442
U19 · FY2005 · CA
Studies of Childhood Solid Tumors$1,604,058
P01 · FY2004 · CA
MTOR as a Therapeutic Target in Childhood Cancer$300,375
R01 · FY2004 · CA
Rapamycin-induced Selective Apoptosis in Malignant Cells$282,000
R01 · FY2004 · CA
Studies of Childhood Solid Tumors$1,558,131
P01 · FY2003 · CA
MTOR as a Therapeutic Target in Childhood Cancer$300,375
R01 · FY2003 · CA
Rapamycin-induced Selective Apoptosis in Malignant Cells$282,000
R01 · FY2003 · CA
Studies of Childhood Solid Tumors$1,554,855
P01 · FY2002 · CA
MTOR as a Therapeutic Target in Childhood Cancer$300,375
R01 · FY2002 · CA
CORE--XENOGRAFT FACILITY$285,821
P01 · FY2002 · CA
RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS$225,703
R01 · FY2002 · CA
MTOR AS THERAPEUTIC TARGET IN PEDIATRIC SOLID TUMORS$0
P01 · FY2002 · CA
CHILDHOOD SOLID TUMORS$1,596,749
P01 · FY2001 · CA
CORE--XENOGRAFT FACILITY$285,821
P01 · FY2001 · CA
CORE--XENOGRAFT FACILITY$285,821
P01 · FY2001 · CA
RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS$233,582
R01 · FY2001 · CA
CHILDHOOD SOLID TUMORS$50,000
P01 · FY2001 · CA
CHILDHOOD SOLID TUMORS$1,607,746
P01 · FY2000 · CA
RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS$290,291
R01 · FY2000 · CA
CORE--XENOGRAFT FACILITY$167,100
P01 · FY2000 · CA